N/A
Manufactured by Par Health USA, LLC
16,089 FDA adverse event reports analyzed
Last updated: 2026-04-15
VASOPRESSIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Par Health USA, LLC. The most commonly reported adverse reactions for VASOPRESSIN include DRUG INEFFECTIVE, OFF LABEL USE, HYPOTENSION, CARDIOGENIC SHOCK, SEPSIS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for VASOPRESSIN.
Out of 4,134 classified reports for VASOPRESSIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 16,089 FDA FAERS reports that mention VASOPRESSIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, HYPOTENSION, CARDIOGENIC SHOCK, SEPSIS, MULTIPLE ORGAN DYSFUNCTION SYNDROME. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Par Health USA, LLC in connection with VASOPRESSIN. Always verify the specific product and NDC with your pharmacist.